European Heart Journal - Cardiovascular Pharmacotherapy

Why a new journal?

Pharmacology is an extremely important part of cardiology today. Nearly every patient with cardiac disease is on some kind of medication. Already there are almost half a million references to ‘cardiovascular pharmacology’ in MEDLINE and the number of papers within this area is growing very fast. More studies are needed to improve outcomes of patients with cardiovascular disease, which is the most common cause of death globally.

Mission Statement:

The official journal of the ESC Working Group on Cardiovascular Pharmacotherapy and a brand new addition to the ESC Journal Family, EHJ - Cardiovascular Pharmacotherapy aims to publish reports specifically describing clinical research relevant to cardiovascular drug therapy.

• Subscribe
• Access online
• Submit manuscript
• Frequently Asked Questions

Contribute to the success of this brand new journal

Submit your paper

Visit the journal's home page 

EHJ: Cardiovascular Pharmacotherapy information

ISSN 2055-6837
Volume 3 - year 2017
4 issues

2017 Public price

173 EUR

2017 Special rates

Members of the Working Group on Cardiovascular Pharmacotherapy
Online: access included in the Membership
Combined (print & online): 103.80 EUR

ESC Constituent Bodies Members
Combined (print & online): 103.80 EUR

ESC Professional/ Professional Plus Members
Combined (print & online): 77.85 EUR

Subscribe here

Editor-in-Chief

Professor Stefan Agewall, (NO), MD PhD, FESC, FACC, is a senior consultant and professor of cardiology at Oslo University Hospital. More than 170 peer-reviewed publications in the cardiovascular field. Chairman of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology 2014-2016. Senior Consulting Editor of the European Heart Journal. Board member of the European Society of Cardiology Committee for Practice Guidelines and Editorial board member of the European Heart Journal.